By Jaime Llinares Taboada
AstraZeneca PLC said Monday that its Enhertu cancer treatment achieved positive results at its first phase III head-to-head trial.
The pharmaceutical company said the trial compared Enhertu with trastuzumab emtansine on patients with HER2-positive breast cancer. HER2 protein overexpression is often associated with aggressive disease and a poor prognosis in breast cancer.
An independent committee concluded that the trial met the primary endpoint of progression-free survival, showing improvements for patients with HER2-positive breast cancer.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
"breast" - Google News
August 09, 2021 at 01:20PM
https://ift.tt/3AtNpLh
AstraZeneca Says Enhertu Improved Survival in Trial Breast-Cancer Patients - MarketWatch
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "AstraZeneca Says Enhertu Improved Survival in Trial Breast-Cancer Patients - MarketWatch"
Post a Comment